18 results about "Eriodictyol" patented technology

The present application relates to a kind of methyltransferase CicOMT10 mutant, preparation method, biological material and application.The methyltransferase mutant is mutated with the amino acid sequence such as SEQ ID NO:1 CicOMT10 enzyme, and the mutation includes: the asparagine of 179th is mutated to alanine;And / or, the threonine of 316th is mutated to alanine.The methyltransferase mutant of the present application can efficiently convert eriodictyol into hesperetin.

The invention relates to the technical field of food characterization recognition and authentic identification, in particular to a characteristic difference metabolite composition of carthamus tinctorius from different producing areas and a screening method and application of the characteristic difference metabolite composition. The characteristic difference metabolite composition is selected from the group consisting of L-phenylalanine, L-citrulline, L-arginine, L-tyrosine, L-asparagine, L-aspartic acid, rutin, quercetin, quercitrin, kaempferol, baicalein, eriodictyol, isoquercitrin, kaempferol-3-O-glucoside, dihydrokaempferol, canthaxanthin, epicatechin, tryptamine and the like; the surfactant is selected from two or more of fumaric acid and betaine. The characteristic difference metabolite composition is obtained by screening through a screening method based on a metabonomics analysis technology, can be used for tracing the origin of safflower, is high in tracing accuracy and simple and convenient to operate, and has good economic benefits and social values.

The present invention belongs to the field of biopharmaceutical technology and specifically relates to a notoginsenoside Fe composition and its use in preparing PTGS2 protein inhibitors and drugs for preventing and treating PTGS2 diseases. The notoginsenoside Fe composition provided by the present invention is composed of notoginsenoside Fe, ginsenoside Rg5, ginsenoside Rk1, quercetin, and eriodictyol. The present invention is the first to discover a novel PTGS2 inhibitor, notoginsenoside Fe, and prepare it into a notoginsenoside Fe composition, providing a new solution for the research and development of drugs for preventing and treating PTGS2-related diseases. The notoginsenoside Fe composition provided by the present invention can reduce the levels of inflammatory factors in mice in colitis, gastritis, and arthritis models, improve colon length, and alleviate foot swelling.

The application relates to a method for bioconversion of naringenin to produce apigenin and dihydroquercetin, belonging to the field of biotechnology and food engineering, and comprising the following steps: (1) screening and mutagenic breeding of high-yield strains; (2) high-density fermentation for converting naringenin into apigenin and dihydroquercetin; and (3) extraction and refining to obtain high-purity apigenin and dihydroquercetin. Rhodococcus opacus OMK-104 bioconversion of cheap and easily available naringenin into high-value apigenin and dihydroquercetin has high conversion rate and high titer of apigenin and dihydroquercetin, and has a positive effect on reducing the production cost of apigenin and dihydroquercetin and promoting large-scale commercial application of apigenin and dihydroquercetin.

The invention discloses application of a recombinant plasmid, a recombinant strain and a preparation in improvement of methyltransferase activity and production of neohesperidin, and belongs to the technical field of bioengineering. The invention aims to solve the technical problems of insufficient YLOMT activity, high eriodictyol residual quantity, low synthesis efficiency, low yield and the like when the yarrowia lipolytica is used for synthesizing neohesperidin in the prior art. The key point of the technical scheme is that a recombinant plasmid is provided, the recombinant plasmid comprises a fusion fragment, and the fusion fragment comprises a coding sequence of a mitochondrial localization signal peptide, a Kozak sequence and a YLOMT coding gene; the amino acid sequence of the mitochondrial positioning signal peptide is shown as SEQ ID NO. 36; the nucleotide sequence of the Kozak sequence is as shown in SEQ ID NO. 37; and the sequence of the YLOMT coding gene is as shown in SEQ ID NO. 38.

The invention relates to a methyltransferase CicOMT10 mutant, a preparation method, a biological material and application. The methyltransferase mutant is formed by mutation of CicOMT10 enzyme with an amino acid sequence as shown in SEQ ID NO: 1. The mutation comprises the following steps: asparagine at the 179th site is mutated into alanine; and / or, threonine at the 316th site is mutated into alanine. The methyltransferase mutant disclosed by the invention can be used for efficiently converting eriodictyol into hesperetin.

The invention provides an application of eriodictyol or a derivative thereof in preparation of a medicine for preventing and / or treating interferon gene stimulating factor (STING) related diseases. The eriodictyol or the derivative thereof can effectively inhibit or reduce STING activation, STING-mediated IFN-I production and / or I-type interferon-induced gene (ISG) production, so as to prevent and / or treat STING-related diseases. The oral bioavailability of eriodictyol or derivatives thereof in an organism is increased by at least 50% compared to known STING antagonists.

The invention belongs to the technical field of medicines, and discloses application of eriodictyol to prevention and treatment of cerebral apoplexy. Specifically, the invention discloses application of eriodictyol as a compound shown in a formula (I) in preparation of drugs for preventing and treating thrombotic stroke. Pharmacological experiments prove that after the eriodictyol is administered for 7 days, neurological function impairment, grasping ability impairment, muscular dystonia and cerebral ischemia volume increase caused by the thrombotic cerebral apoplexy can be obviously improved, which indicates that the eriodictyol has obvious pharmacological activity for preventing and treating the thrombotic cerebral apoplexy. Therefore, the eriodictyol can be used for preparing the medicine for preventing and treating the cerebral apoplexy, and has relatively high clinical application value and development prospect.

The present invention provides compositions comprising ruscogenin. The compositions of the present invention can be topically applied to the skin of a subject. The present invention further provides methods of applying compositions comprising ruscogenin to improve or treat a skin condition. The compositions of the present invention can also be applied to improve the overall appearance of the skin.

The application provides flavone 3beta-hydroxylase mutants and coenzyme mutants thereof, and is used for catalyzing synthesis of eriodictyol. Specifically, the application obtains flavone 3beta-hydroxylase mutants and coenzyme mutants thereof with an overall 10-fold performance improvement through artificial intelligence and high-throughput screening, and the mutants can be used to catalyze naringenin to produce 30g / L of eriodictyol with a yield of more than 95%.

The embodiment of the invention discloses a drought stress method for Artemisia impatiens and application. The method comprises the following steps: selecting seeds of Artemisia impatiens with full grains and uniform size, disinfecting, sowing in a culture dish, placing in a culture box, and transferring germs into a plastic basin for sunlight greenhouse culture after germination; the seedlings are subjected to drought stress treatment under the conditions that the concentration of PEG-6000 ranges from 5% to 30%, and the time ranges from 2 d to 6 d. According to the method, Artemisia impatiens is selected as a research object, two drought stress conditions of soil water content and PEG-6000 solution are set, and the influence of drought stress on physiological and biochemical characteristics of Artemisia impatiens seedlings and the content of eriodictyol-7-methyl ether and isosakuranetin with anti-inflammatory and asthma-relieving activities is discussed. Furthermore, TGF-beta1 is used for inducing mouse airway smooth muscle cells to construct an asthma model, and it is verified that the artemisia differentiata can effectively improve the asthma relieving activity after being subjected to drought stress. The method provides a theoretical basis for high-quality and high-efficiency cultivation of Artemisia impatiens.

A method for producing eriodictyol and dihydroquercetin by biotransformation of naringenin belongs to the field of biotechnology and food engineering, and comprises the following steps: (1) screening and mutation breeding of high-yield strains; (2) converting naringenin into eriodictyol and dihydroquercetin through high-density fermentation; and (3) extracting and refining to obtain high-purity eriodictyol and dihydroquercetin. According to the method disclosed by the invention, the Rhodococcus opacus OMK-104 subjected to multiple rounds of ARTP mutation breeding is used for biologically converting the naringenin which is low in price and easy to obtain into the eriodictyol and the dihydroquercetin with high additional value, the conversion rate is high, the titers of the eriodictyol and the dihydroquercetin are high, and the method has a good application prospect in reducing the production cost of the eriodictyol and the dihydroquercetin. And the method plays a positive role in promoting large-scale commercial application of eriodictyol and dihydroquercetin.

The invention discloses a phyllostachys pubescens flavone synthase I gene PeFNSI1, an encoded protein and an application of the phyllostachys pubescens flavone synthase I gene PeFNSI1, belongs to the technical field of genetic engineering, and particularly relates to the phyllostachys pubescens flavone synthase I gene PeFNSI1, the nucleotide sequence of the phyllostachys pubescens flavone synthase I gene PeFNSI1 is shown as SEQ ID NO.1, and the application of the phyllostachys pubescens flavone synthase I gene PeFNSI1 in enhancing The invention reveals for the first time that flavone synthetase I (PeFNSI) coded by the phyllostachys pubescens PeFNSI1 gene can specifically catalyze flavone precursor naringenin to be converted into apigenin and catalyze eriodictyol to be converted into luteolin, and can activate a'bifunctional 'regulation element of a flavone synthesis and salicylic acid defense pathway at the same time by reprogramming salicylic acid metabolic flux, so that the flavone synthetase I (PeFNSI) can be used for preparing the apigenin and the luteolin. The multi-element synergistic effect of flavone synthesis, salicylic acid metabolic flux regulation and control and disease resistance enhancement is achieved, the limitation of an existing disease resistance strategy is broken through, and a brand new molecular tool is provided for plant disease resistance breeding.

The application discloses a kind of temperature-sensitive recombinant collagen sterile mask and preparation method thereof.The mask is by hydroxypropyl chitin 1wt%-3.5wt%, recombinant III type humanized collagen 0.01wt%-0.5wt%, recombinant I type humanized collagen 0.01wt%-0.5wt%, glycerol 0.1wt%-10wt%, eriodictyol 0.001wt%-0.015wt%, asiaticoside 0.1wt%-2wt% and water according to mass percentage.The sterile mask of the application is in the form of viscous liquid below 25 DEG C, each efficacy component can be uniformly distributed in system, when coating to face, temperature increases to body temperature, solution phase transition occurs, quickly converts into weak gel, can realize the rapid penetration and sustained release efficacy component to skin to skin, reach deep instant relief and skin repair effect.

The invention relates to the technical field of agricultural biology, in particular to a lipid-lowering eriodictyol-containing rubber seed three-stage isolate and application thereof. According to the method, an ultrasonic extraction technology is adopted, an extraction technology for optimizing total flavonoid compounds in natural rubber seeds is adopted, a rubber seed crude extract with high flavonoid substance content is obtained, three-stage isolates of the rubber seed extract containing eriodictyol active ingredients are separated through a multi-stage preparation technology, and the lipid-lowering effect of the rubber seed extract is verified on the cellular level.

The present invention relates to methods and transformed host cells for the production of eriodictyol from naringenin via bioconversion.

The invention discloses an application of a natural Tau-tubulin kinase 1 (TTBK1) inhibitor in anti-meningioma drugs, and belongs to the field of medicinal chemistry, the natural product is named eriodictyol-7-O-beta-D-glucuronic acid methyl ester, can form a novel and unique hydrogen bond with TTBK1, has a hydrophobic effect, can increase the ROS level in meningioma cells, and can be used for preparing anti-meningioma drugs. The action mechanism is unique, and structural design guidance is provided for TTBK1 inhibitor drug design. The compound can be used for preparing medicines for resisting malignant meningioma.

The present invention relates to a methyltransferase (CitOMT) mutant, its preparation method, biomaterial, and application. The methyltransferase mutant is derived from a CitOMT enzyme with an amino acid sequence as shown in SEQ ID NO:1, wherein the mutations include: a mutation of phenylalanine at position 164 to alanine; and / or a mutation of glutamine at position 238 to alanine. The methyltransferase mutant of the present invention is capable of efficiently converting eriodictyol into homoeriodictyol.